690 related articles for article (PubMed ID: 21420247)
1. Phase II trial of radiotherapy after hyperbaric oxygenation with multiagent chemotherapy (procarbazine, nimustine, and vincristine) for high-grade gliomas: long-term results.
Ogawa K; Ishiuchi S; Inoue O; Yoshii Y; Saito A; Watanabe T; Iraha S; Toita T; Kakinohana Y; Ariga T; Kasuya G; Murayama S
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):732-8. PubMed ID: 21420247
[TBL] [Abstract][Full Text] [Related]
2. Hyperfractionated radiotherapy and multi-agent chemotherapy (procarbazine, ACNU and vincristine) for high-grade gliomas: a prospective study.
Ogawa K; Yoshii Y; Toita T; Saito A; Kakinohana Y; Iraha S; Sugimoto K; Tsuchida Y; Tamaki W; Adachi G; Hyodo A; Murayama S
Anticancer Res; 2006; 26(3B):2457-62. PubMed ID: 16821632
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of radiotherapy after hyperbaric oxygenation with chemotherapy for high-grade gliomas.
Ogawa K; Yoshii Y; Inoue O; Toita T; Saito A; Kakinohana Y; Adachi G; Iraha S; Tamaki W; Sugimoto K; Hyodo A; Murayama S
Br J Cancer; 2006 Oct; 95(7):862-8. PubMed ID: 16953239
[TBL] [Abstract][Full Text] [Related]
4. Prospective trial of radiotherapy after hyperbaric oxygenation with chemotherapy for high-grade gliomas.
Ogawa K; Yoshii Y; Inoue O; Toita T; Saito A; Kakinohana Y; Adachi G; Ishikawa Y; Kin S; Murayama S
Radiother Oncol; 2003 Apr; 67(1):63-7. PubMed ID: 12758241
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy.
Mizoe JE; Tsujii H; Hasegawa A; Yanagi T; Takagi R; Kamada T; Tsuji H; Takakura K;
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):390-6. PubMed ID: 17459607
[TBL] [Abstract][Full Text] [Related]
6. Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas.
Levin VA; Prados MR; Wara WM; Davis RL; Gutin PH; Phillips TL; Lamborn K; Wilson CB
Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):75-83. PubMed ID: 7721642
[TBL] [Abstract][Full Text] [Related]
7. [Chemotherapy of recurrent supratentorial malignant gliomas (phase II study)].
Afra D; Sipos L; Vitanovics D
Ideggyogy Sz; 2002 Jan; 55(1-2):38-44. PubMed ID: 12122942
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305).
Shibui S; Narita Y; Mizusawa J; Beppu T; Ogasawara K; Sawamura Y; Kobayashi H; Nishikawa R; Mishima K; Muragaki Y; Maruyama T; Kuratsu J; Nakamura H; Kochi M; Minamida Y; Yamaki T; Kumabe T; Tominaga T; Kayama T; Sakurada K; Nagane M; Kobayashi K; Nakamura H; Ito T; Yazaki T; Sasaki H; Tanaka K; Takahashi H; Asai A; Todo T; Wakabayashi T; Takahashi J; Takano S; Fujimaki T; Sumi M; Miyakita Y; Nakazato Y; Sato A; Fukuda H; Nomura K
Cancer Chemother Pharmacol; 2013 Feb; 71(2):511-21. PubMed ID: 23228988
[TBL] [Abstract][Full Text] [Related]
9. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.
Levin VA; Uhm JH; Jaeckle KA; Choucair A; Flynn PJ; Yung WKA ; Prados MD; Bruner JM; Chang SM; Kyritsis AP; Gleason MJ; Hess KR
Clin Cancer Res; 2000 Oct; 6(10):3878-84. PubMed ID: 11051233
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II trial of hyperfractionated concomitant boost proton radiotherapy for supratentorial glioblastoma multiforme.
Mizumoto M; Tsuboi K; Igaki H; Yamamoto T; Takano S; Oshiro Y; Hayashi Y; Hashii H; Kanemoto A; Nakayama H; Sugahara S; Sakurai H; Matsumura A; Tokuuye K
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):98-105. PubMed ID: 19695794
[TBL] [Abstract][Full Text] [Related]
11. A sequential chemo-radiotherapeutic treatment for patients with malignant gliomas: a phase II pilot study.
Dazzi C; Cariello A; Giannini M; Del Duca M; Giovanis P; Fiorentini G; Leoni M; Rosti G; Turci D; Tienghi A; Vertogen B; Zumaglini F; De Giorgi U; Marangolo M
Anticancer Res; 2000; 20(1B):515-8. PubMed ID: 10769716
[TBL] [Abstract][Full Text] [Related]
12. High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients.
Durando X; Lemaire JJ; Tortochaux J; Van-Praagh I; Kwiatkowski F; Vincent C; Bailly C; Verrelle P; Irthum B; Chazal J; Bay JO
Bone Marrow Transplant; 2003 Apr; 31(7):559-64. PubMed ID: 12692621
[TBL] [Abstract][Full Text] [Related]
13. High-dose BCNU and autologous progenitor cell transplantation given with intra-arterial cisplatinum and simultaneous radiotherapy in the treatment of high-grade gliomas: benefit for selected patients.
Fernández-Hidalgo OA; Vanaclocha V; Vieitez JM; Aristu JJ; Rebollo J; Gúrpide A; Aramendía JM; Moreno-Palanques R; Martín-Algarra S; Subirá ML; Brugarolas A
Bone Marrow Transplant; 1996 Jul; 18(1):143-9. PubMed ID: 8832007
[TBL] [Abstract][Full Text] [Related]
14. Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26).
Vordermark D; Ruprecht K; Rieckmann P; Roggendorf W; Vince GH; Warmuth-Metz M; Kölbl O; Flentje M
BMC Cancer; 2006 Oct; 6():247. PubMed ID: 17049083
[TBL] [Abstract][Full Text] [Related]
15. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.
Prados MD; Seiferheld W; Sandler HM; Buckner JC; Phillips T; Schultz C; Urtasun R; Davis R; Gutin P; Cascino TL; Greenberg HS; Curran WJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1147-52. PubMed ID: 15001257
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy in supratentorial gliomas. A study of 821 cases.
Heesters M; Molenaar W; Go GK
Strahlenther Onkol; 2003 Sep; 179(9):606-14. PubMed ID: 14628126
[TBL] [Abstract][Full Text] [Related]
17. Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study.
Jeremic B; Grujicic D; Antunovic V; Djuric L; Stojanovic M; Shibamoto Y
Int J Radiat Oncol Biol Phys; 1994 Dec; 30(5):1179-85. PubMed ID: 7961028
[TBL] [Abstract][Full Text] [Related]
18. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas.
Levin VA; Hess KR; Choucair A; Flynn PJ; Jaeckle KA; Kyritsis AP; Yung WK; Prados MD; Bruner JM; Ictech S; Gleason MJ; Kim HW
Clin Cancer Res; 2003 Mar; 9(3):981-90. PubMed ID: 12631596
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of nimustine, carboplatin, vincristine, and interferon-beta with radiotherapy for glioblastoma multiforme: experience of the Kyoto Neuro-Oncology Group.
Aoki T; Takahashi JA; Ueba T; Oya N; Hiraoka M; Matsui K; Fukui T; Nakashima Y; Ishikawa M; Hashimoto N
J Neurosurg; 2006 Sep; 105(3):385-91. PubMed ID: 16961130
[TBL] [Abstract][Full Text] [Related]
20. Supratentorial glioblastoma treated with radiotherapy: use of the Radiation Therapy Oncology Group recursive partitioning analysis grouping for predicting survival.
Fujii O; Soejima T; Kuwatsuka Y; Harada A; Ota Y; Tsujino K; Sasaki M; Kudo H; Nishihara M; Taomoto K
Jpn J Clin Oncol; 2010 Aug; 40(8):726-31. PubMed ID: 20410057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
